Finasteride: Nursing Drug Guide, PSA Monitoring & Pregnancy Risk

Finasteride is available as generic film-coated tablets and under the brand names Proscar (5 mg for benign prostatic hyperplasia) and Propecia (1 mg for male pattern alopecia). Do not confuse finasteride with dutasteride (another 5α-reductase inhibitor) or with alpha-blockers such as doxazosin used for the same urinary symptoms.

Tablet appearance differs by strength and manufacturer—always match the MAR to the dispensed product name, strength, and indication. PROSCAR 5 mg tablets are blue; PROPECIA 1 mg tablets are tan per labeling.

Finasteride is a Type II 5α-reductase inhibitor indicated for men with symptomatic BPH and an enlarged prostate (5 mg) and for male pattern hair loss (1 mg) per PROSCAR and PROPECIA prescribing information. PROSCAR is not approved for prostate cancer prevention; labeling warns that 5α-reductase inhibitors may increase the risk of high-grade prostate cancer.

↔On a small screen, swipe or scroll sideways to see the full table.

Finasteride selectively inhibits Type II 5α-reductase, blocking conversion of testosterone to dihydrotestosterone (DHT). Lower DHT shrinks prostate tissue over months in BPH and slows hair miniaturization in androgenetic alopecia per labeling.

Because DHT is required for normal development of male external genitalia in utero, fetal exposure carries teratogenic risk—this drives the pregnancy contraindication and warnings about crushed or broken tablets. Median serum testosterone may rise while remaining in the physiologic range per PROSCAR labeling.

BPH: 5 mg (one tablet) orally once daily, with or without meals. May be used alone or with the alpha-blocker doxazosin per prescriber order. Hair loss: 1 mg once daily. Swallow tablets whole; do not crush, chew, or split unless pharmacy provides an approved alternative.

Missed dose: Not specified in the reviewed prescribing information—take when remembered if due; do not double doses; contact pharmacist if multiple consecutive doses were missed.

Pediatrics: Not indicated for pediatric patients per labeling.

Pretreatment checks

• Confirm male patient, correct indication, and matching strength (5 mg BPH vs 1 mg hair loss)
• Ask about household contacts who are pregnant or may become pregnant; plan safe tablet storage and handling
• Baseline PSA and urology history for BPH—establish new PSA baseline ≥6 months after starting 5 mg therapy
• Screen for history of depression or suicidal thoughts per BNF/MHRA safety communications
• Review allergy history to finasteride, dutasteride, or other 5α-reductase inhibitors
• Concurrent alpha-blocker (e.g., doxazosin) or duplicate 5α-reductase inhibitor on the MAR

Contraindications

• Pregnancy—finasteride may cause fetal harm; contraindicated in females who are or may potentially be pregnant
• Hypersensitivity to any component of finasteride

Important warnings (labeling)

↔On a small screen, swipe or scroll sideways to see the full table.

Selected interactions

PROSCAR labeling states no drug interactions of clinical importance have been identified; finasteride does not appear to affect the cytochrome P450 system. It has been used concomitantly with acetaminophen, alpha-blockers, ACE inhibitors, NSAIDs, and warfarin without clinically meaningful interactions in clinical studies. Always verify the full medication profile at transitions of care.

• Follow medication administration rights—oral film-coated tablet with water
• Swallow tablets whole; do not crush, chew, or split unless pharmacy approves an alternative formulation
• If enteral tube administration is requested, not specified in the reviewed prescribing information—clarify with pharmacy rather than crushing
• May take with or without food per labeling
• Store securely away from pregnant household members and children; discard broken tablet fragments safely

Symptom improvement in BPH may take months—labeling and BNF note benefit may require several months of therapy. Track decreased frequent urination, weak stream, or urinary incontinence alongside urinary output and retention episodes per protocol.

For 1 mg hair-loss therapy, visible benefit may require ≥3 months of daily use; withdrawal leads to reversal within about 12 months per PROPECIA labeling. PSA should fall on 5 mg BPH therapy—use adjusted interpretation, not untreated reference ranges alone.

• Pregnant or possibly pregnant person exposed to crushed or broken finasteride—wash contact area; urgent prescriber and maternal–fetal risk guidance per facility protocol
• Facial or tongue swelling, difficulty breathing, or widespread rash—suspect anaphylaxis or angioedema; emergency pathway
• New or worsening depression, hopelessness, or suicidal thoughts—urgent mental-health escalation; consider holding finasteride per prescriber and BNF guidance
• Confirmed PSA increase from lowest value on finasteride 5 mg—evaluate for prostate cancer even if “normal” for untreated men
• Acute urinary retention, hematuria, or systemic symptoms suggesting infection or obstruction—urgent urology assessment
• New breast lump, nipple discharge, or persistent breast pain—report per labeling breast-disorder monitoring
• Suspected overdose—supportive care; no specific antidote recommended in labeling

Most common drug-related adverse reactions (≥1% and more frequent than placebo) in the 4-year PROSCAR BPH trial per labeling: impotence, decreased libido, decreased ejaculate volume, and breast enlargement/tenderness. Postmarketing reports include depression, suicidal ideation, persistent sexual dysfunction after discontinuation, male infertility, testicular pain, hematospermia, and male breast cancer.

↔On a small screen, swipe or scroll sideways to see the full table.

When combined with doxazosin, labeling notes higher rates of abnormal ejaculation, impotence, decreased libido, and dizziness than either drug alone. Sexual adverse reactions may persist after discontinuation; the independent role of finasteride is unknown per labeling.

Clinical studies administered single finasteride doses up to 400 mg and multiple doses up to 80 mg/day for three months without adverse reactions per PROSCAR overdosage labeling.

There is no specific antidote for finasteride. Labeling states that until further experience is obtained, no specific overdose treatment can be recommended—provide symptomatic and supportive care. Mean elimination half-life is approximately 6 hours in adults (longer in older men) per labeling.

For suspected overdose, contact local poison control or toxicology services and emergency care per facility protocol—not country-specific hotlines in patient-facing teaching.

• Proscar 5 mg vs Propecia 1 mg—same generic name, different indications; verify strength on MAR, blister pack, and pharmacy label every time
• Finasteride vs dutasteride—both 5α-reductase inhibitors; confirm correct drug, strength, and dosage form
• Do not crush or split without pharmacy approval—LASA risk includes exposing pregnant staff or family to tablet contents
• Use medication reconciliation at transitions—avoid duplicate 5α-reductase inhibitors or wrong-strength substitution
• Barcode scan when available; separate look-alike urology or dermatology tablets in storage

• Ask privately about sexual function, mood, and sleep—patients may not volunteer impotence, libido loss, or low mood
• If on doxazosin combination, assess orthostatic symptoms when standing—document low testosterone-related concerns only when clinically relevant to reported symptoms
• Discourage pill cutters for finasteride when a pregnant household member may contact fragments
• Clarify when PSA blood draw is due and that results must be interpreted on 5 mg therapy
• Confirm dispensed tablet matches indication before first clinic dose after pharmacy refill

• Pregnancy—contraindicated in females who are or may become pregnant; crushed or broken tablets must not be handled by pregnant contacts
• Lactation / partner exposure—finasteride is not indicated for females; present in semen per labeling—BNF advises condom use if partner is pregnant or may become pregnant; breastfeeding-specific guidance for partners of male patients is not specified in the reviewed prescribing information
• History of depression or suicidal ideation—heightened psychiatric monitoring per BNF/MHRA safety communications
• Fertility planning—semen volume and sperm parameters may decrease; effects on individual fertility unknown per labeling
• Elevated baseline PSA or prior negative biopsy—cancer detection requires adjusted PSA thresholds and urology follow-up
• Hepatic impairment—not studied; finasteride is extensively metabolized in the liver—use prescriber guidance
• Geriatric men—half-life may be longer (~8 h vs ~6 h); no dosage adjustment required per labeling

↔On a small screen, swipe or scroll sideways to see the full table.

Vitals: routine per setting; if on doxazosin combo, document orthostatic blood pressure when dizziness reported. Labs beyond PSA: not specified in the reviewed prescribing information for routine monitoring—follow urology and primary care plans.

• Take the correct strength daily—5 mg for prostate symptoms, 1 mg for hair loss; do not switch strengths without prescriber approval
• Swallow tablets whole—pregnant women must not touch crushed or broken tablets; wash skin with soap and water if exposure occurs
• PSA tests will look lower on 5 mg therapy—always tell providers and labs you take finasteride
• Report breast changes, allergic swelling, urinary retention, worsening voiding symptoms, low mood, or suicidal thoughts promptly
• Discuss sexual side effects openly—changes may continue after stopping; prescriber may adjust therapy
• Finasteride is not for prostate cancer prevention and may increase high-grade cancer detection—keep scheduled urology follow-up
• If partner is pregnant or may become pregnant, use condoms during intercourse per BNF guidance on semen exposure
• Hair-loss benefit may take ≥3 months; stopping therapy reverses effect within about 12 months per PROPECIA labeling

Do not give and contact the prescriber or pharmacist when:

Hold parameters may vary by institutional protocol. Because sexual and psychiatric effects may persist after stopping, document symptom timing and prescriber guidance on restart.

Practice NCLEX-style clinical judgment practice for finasteride using a tabbed outpatient case (MAR · Labs · History · Nursing notes) focused on strength verification, crushed-tablet pregnancy exposure, PSA halving rules, and depression screening—then work through priority action, SATA cue recognition, PSA trend interpretation, ordered exposure-response steps, overdose cloze, and matrix urgency sorting: recognise cues → analyse → prioritise → act → evaluate outcomes.

Unfolding case. Martin is a 68-year-old with BPH on finasteride 5 mg daily plus doxazosin 8 mg for 7 months. His wife, who is 10 weeks pregnant, cleaned up fragments after he split a tablet with a pill cutter. Clinic staff ask you to review the case tabs before today’s dose.

This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.

• Editorial Policy
• Medical Review Process
• Disclaimer

Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.